Abstract
The identification of protein biomarkers for acute myeloid leukemia (AML) that could find applications in AML diagnosis and prognosis, treatment and the selection for bone marrow transplant requires substantial comparative analyses of the proteomes from AML patients. In the past years, several studies have suggested some biomarkers for AML diagnosis or AML classification using methods for sample preparation with low proteome coverage and low resolution mass spectrometers. However, most of the studies did not follow up, confirm or validate their candidates with more patient samples. Current proteomics methods, new high resolution and fast mass spectrometers allow the identification and quantification of several thousands of proteins obtained from few tens of μg of AML cell lysate. Enrichment methods for posttranslational modifications (PTM), such as phosphorylation, can isolate several thousands of site-specific phosphorylated peptides from AML patient samples, which subsequently can be quantified with high confidence in new mass spectrometers. While recent reports aiming to propose proteomic or phosphoproteomic biomarkers on the studied AML patient samples have taken advantage of the technological progress, the access to large cohorts of AML patients to sample from and the availability of appropriate control samples still remain challenging.
Keywords: Acute myeloid leukemia, biomarker, mass spectrometry, proteomics, phosphoproteomics, diagnosis, prognosis.
Current Pharmaceutical Biotechnology
Title:Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Volume: 17 Issue: 1
Author(s): Elise Aasebø, Rakel B. Forthun, Frode Berven, Frode Selheim and Maria Hernandez-Valladares
Affiliation:
Keywords: Acute myeloid leukemia, biomarker, mass spectrometry, proteomics, phosphoproteomics, diagnosis, prognosis.
Abstract: The identification of protein biomarkers for acute myeloid leukemia (AML) that could find applications in AML diagnosis and prognosis, treatment and the selection for bone marrow transplant requires substantial comparative analyses of the proteomes from AML patients. In the past years, several studies have suggested some biomarkers for AML diagnosis or AML classification using methods for sample preparation with low proteome coverage and low resolution mass spectrometers. However, most of the studies did not follow up, confirm or validate their candidates with more patient samples. Current proteomics methods, new high resolution and fast mass spectrometers allow the identification and quantification of several thousands of proteins obtained from few tens of μg of AML cell lysate. Enrichment methods for posttranslational modifications (PTM), such as phosphorylation, can isolate several thousands of site-specific phosphorylated peptides from AML patient samples, which subsequently can be quantified with high confidence in new mass spectrometers. While recent reports aiming to propose proteomic or phosphoproteomic biomarkers on the studied AML patient samples have taken advantage of the technological progress, the access to large cohorts of AML patients to sample from and the availability of appropriate control samples still remain challenging.
Export Options
About this article
Cite this article as:
Aasebø Elise, Forthun B. Rakel, Berven Frode, Selheim Frode and Hernandez-Valladares Maria, Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients, Current Pharmaceutical Biotechnology 2016; 17 (1) . https://dx.doi.org/10.2174/1389201016666150826115626
DOI https://dx.doi.org/10.2174/1389201016666150826115626 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide
Recent Patents on Anti-Cancer Drug Discovery Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Histone Deacetylase Inhibitors and Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets STAT5 and STAT5 Inhibitors in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality
Reviews on Recent Clinical Trials Epigenetics and Adult Acute Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Pharmacogenomics: The Influence of Genomic Variation on Drug Response
Current Topics in Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews